

## ORIGINAL PAPER

# Research of the effect of cold atmospheric plasma on gluten proteins from gluten-free flour

Vesna Gojković Cvjetković<sup>1</sup> | Željka Marjanović-Balaban<sup>2</sup> | Dragan Vujadinović<sup>1</sup> | Milan Vukić<sup>1</sup> | Marko Ivanović<sup>1</sup>

<sup>1</sup>University of East Sarajevo, Faculty of Technology Zvornik, Karakaj 34A, 75400 Zvornik, Republic of Srpska, Bosnia and Herzegovina

<sup>2</sup>University of Banja Luka, Faculty of Forestry, 75a Vojvode Stepe Stepanovića Blvd., 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina

## Correspondence

Vesna Gojković Cvjetković, University of East Sarajevo, Faculty of Technology Zvornik, Karakaj 34A, 75400 Zvornik, Republic of Srpska, Bosnia and Herzegovina  
Email: vesna.gojkovic@tfzv.ues.rs.ba

## Abstract

A gluten-free diet is the only available therapy for people with celiac disease (CD) and wheat allergy (WA). Given that this type of diet is difficult to implement because there is a possibility that gluten-free products could be contaminated with gluten, the aim of this paper was to examine the effect of cold plasma treatment on gluten proteins present in gluten-free flour. Samples were treated in a solid state (4 min) and as extracts (1 min). After treatment, proteins were separated on an HPLC apparatus. Then, the samples that were treated (in the solid form and as extracts) were compared to the untreated samples. Based on the obtained results, fewer proteins were isolated from the samples that were treated, compared to the untreated ones.

**Keywords:** gluten, gluten-free flour, cold atmospheric plasma (CAP), RP-HPLC

## 1. INTRODUCTION

For people who suffer from celiac disease (CD), wheat allergies (WA) and non-celiac gluten sensitivity, consumption of food containing gluten can lead to serious health consequences (Elli et al. 2015; Serena, D'Avino, & Fasano 2020). Gluten is the main protein of wheat. It contains fractions that are toxic. These are gliadins (monomeric proteins) and glutenins (polymeric proteins) (Balakireva & Zamyatnin 2016; Shewry 2019; Wieser 2007). Gliadins are separated chromatographically into four fractions ( $\omega 5$ ,  $\omega 1,2$ ,  $\alpha + \beta$  and  $\gamma$ ) and glutenins into three ( $\omega b$  gliadins, HMW and LMW glutenins) (Pillolli et al. 2019; Schalk, Lexhaller, Koehler, & Scherf 2017). Gluten proteins are responsible for the elasticity and stretchability of dough (Kumar 2014; Rai, Kaur, & Chopra 2018). In the United States and Northern Europe, celiac disease (CD) affects about 1% of the population (Gujral 2012; Taraghikhah et al. 2020). It is one of the most common hypersensitive conditions (Gumienna & Górna 2020). Pathogenic microorganisms, the time of eating food containing gluten, and breastfeeding are

also factors influencing the development of this disease (Caminero & Verdu 2019; Lionetti & Catassi 2015; Silano 2010). The most common symptoms that occur in people who are suffering from this disease are stomach pain, diarrhea, constipation, weight loss, and inflammation of the small intestine (Caio et al. 2019). A wheat allergy is an allergy that occurs as a result of a reaction to wheat proteins. The symptoms are similar to those that occur when people are allergic to other products. These are rashes on the skin, difficulty breathing, and, in the most severe cases, anaphylaxis and possibly death (Cianferoni 2016; El-Sayed & Shousha 2020). Non-celiac gluten sensitivity occurs when symptoms similar to celiac disease appear, but it is not understood how the immune system might be involved (Holmes 2013; Sergi, Villanacci, & Carroccio 2021). A gluten-free diet is the only available therapy for people with celiac disease (CD) and wheat allergy (WA) (Itzlinger, Branchi, Elli, & Schumann 2018). According to the *Codex Alimentarius* standard, gluten-free food is food that has a natural deficiency or an acceptable level of gluten (<20 mg/kg) (Codex Alimentarius Commission

and others 2008). People who need to eat a gluten-free diet can eat foods that naturally do not contain gluten, such as meat, fish, dairy products, vegetables, nuts, fruits, and gluten-free grains. These are rice, corn, millet and pseudocereals such as amaranth and buckwheat (Saturni, Ferretti, & Bacchetti 2010; Wieser, Segura, Ruiz-Carnicer, Sousa, & Comino 2021). Gluten-containing raw materials from wheat, rye, and barley can be made gluten-free by specialized processing, such as starch washing, peptidase treatment for beverages, and the use of gluten-free strains (Khairuddin & Lasekan 2021; Walter 2014). Implementing a gluten-free diet is difficult because there is a possibility of unintentional contamination of products with gluten, improper declaration, social restrictions, and the presence of gluten proteins in food and pharmaceutical products (Wieser, Ruiz-Carnicer, Segura, Comino, & Sousa 2021). Contamination of gluten-free foods with gluten can occur at many stages of food production and also in households (Wieser, Ruiz-Carnicer, et al. 2021; Wieser, Segura, et al. 2021). Today, there are numerous methods for determining gluten proteins in food products. The following methods are the most commonly used: isoelectric focusing (IEF), sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE), reversed-phase high pressure liquid chromatography (RP-HPLC), exclusion chromatography (SE-HPLC), high-pressure zone electrophoresis (HPCE), coupled liquid chromatography-mass spectrometry (LC-MS/MS), enzyme-immunochemical method (ELISA), and polymerase chain reaction (PCR) (Gojković-Cvjetković et al. 2019; Vensel, Tanaka, & Altenbach 2014). Given that a gluten-free diet is difficult to implement because there is a possibility of accidental contamination of products with gluten during production, processing, transport, and storage, the aim of this paper was to examine the effect of cold plasma treatment on gluten proteins obtained from gluten-free flour. After plasma treatment, the proteins were separated by RP-HPLC chromatography and the treated samples (in the solid state and as extracts) were compared to the untreated samples.

## 2. MATERIALS AND METHODS

Gluten-free flour samples in the solid form (protein content 3.6 g/100 g) and their extracts were treated with cold atmospheric plasma. Gliadin and glutenin extracts were obtained according to the modified method of Wieser, Antes, and Seilmeier (1998) (Gojković-Cvjetković et al. 2019). Gliadin was extracted with 70% (v/v) ethanol, and glutenins were extracted with 50% (v/v) 1-propanol to which Tris-HCl was added (0.05 mol/l, pH=7.5), urea (2 mol/l) and dithioerythritol (DTT, 1%). Prior to anal-

ysis on an HPLC apparatus, the samples were filtered through a 0.45  $\mu\text{m}$  filter.

### 2.1. Measurement procedure

Gluten-free flour samples in a solid state and their extracts were treated with cold atmospheric plasma. The treatment was done using a custom-built device composed of a dielectric barrier source (SDBD) attached to the top cover of a plastic box. The samples were placed in the box that was tightly closed with a lid. The plasma was ignited in the surrounding air. During the treatment, the input frequency was 50 Hz and the input voltage was 50 V. The samples in the solid state were treated for 4 minutes and the extracts for 1 minute.

### 2.2. RP-HPLC chromatography

After plasma treatment gliadin and glutenin separation was performed on an HPLC apparatus (Agilent Technologies 1260 Infinity). It was performed on a column (Zorbax 300 SB-C3 Agilent), set at 45 °C (gliadins) and 40 °C (glutenins) for 16.0 min (gliadins) and 21.0 min (glutenins). Absorbance was measured at 210 and 280 nm. Separation was performed according to the modified method of Gojković-Cvjetković et al. (2019).

### 2.3. Statistical analysis of results

For the statistical analysis of the results IBM SPSS Statistics 26 was used. The average amount of proteins ( $X_{av}$ ), standard deviation (SD), std. error, min and max value were calculated. In order to examine the effect of cold plasma treatment on the average amount of proteins and their relative concentration, a one-way analysis of variance with different groups was used. The significance of differences between the average amounts at the  $p=0.05$  level was assessed by post-hoc Tukey' HSD tests.

## 3. RESULTS AND DISCUSSION

Table 1 shows the total amount of gliadin proteins (TAP), the amount of protein within fractions ( $\omega 5$ ,  $\omega 1.2$ ,  $\alpha + \beta$  and  $\gamma$  gliadins) obtained from gluten-free flour samples and separated on an HPLC apparatus, with absorbance measured at 210 nm.

Based on the obtained results, the highest amount of protein was obtained from T1 samples ( $X_{av}=15.17$ ), and the lowest from T3 samples ( $X_{av}=9.33$ ). The effect of cold plasma treatment on the total amount of protein was investigated by one-factor analysis of variance of different groups. It was found that there is a statistically significant

**Table 1.** TAP and amount of gliadin proteins by fractions ( $\omega 5$ ,  $\omega 1,2$ ,  $\alpha + \beta$  and  $\gamma$  gliadins) from gluten-free flour observed during RP-HPLC analysis; solvent: 70% (v/v) ethanol; absorbance measurement at 210 nm.

Treatments		N	Xav	SD	Std. Error	Min	Max
Total amount of proteins (TAP)	T1	6	15.17	0.98	0.40	14	16
	T2	6	12.00	1.26	0.52	11	14
	T3	6	9.33	0.82	0.33	8	10
$\omega 5$ gliadins	T1	6	1.67	0.52	0.21	1	2
	T2	6	2.17	0.41	0.17	2	3
	T3	6	1.17	0.41	0.17	1	2
$\omega 1,2$ gliadins	T1	6	3.00	0.63	0.26	2	4
	T2	6	2.83	0.75	0.31	2	4
	T3	6	1.83	0.75	0.31	1	3
$\alpha + \beta$ gliadins	T1	6	5.17	0.41	0.17	5	6
	T2	6	4.50	0.84	0.34	4	6
	T3	6	3.83	0.98	0.40	3	5
$\gamma$ gliadins	T1	6	5.33	0.52	0.21	5	6
	T2	6	2.50	0.55	0.22	2	3
	T3	6	2.50	0.55	0.22	2	3
ANOVA (TNP)		F(2.15)=47.47, Sig.=0.000, eta square=102.33/118.50=0.86					
ANOVA ( $\omega 5$ )		F(2.15)=7.50, Sig.=0.005<0.05, eta square=3/6=0.50					
ANOVA ( $\omega 1,2$ )		F(2.15)=4.67, Sig.=0.03<0.05, eta square=4.78/12.44=0.38					
ANOVA ( $\alpha + \beta$ )		F(2.15)=4.36, Sig.=0.03<0.05, eta square=5.33/14.50=0.37					
ANOVA ( $\gamma$ )		F(2.15)=55.58, Sig.=0.000, eta square=32.11/36.44=0.88					

T1 – CONTROL, T2 – extracts treated with plasma for 4 min and T3-extracts treated for 1 min after extraction.  
Xav – the average amount of isolated proteins, SD – standard deviation.

difference,  $F(2.15)=47.47$ ,  $\text{Sig.}=0.000<0.05$ . A post-hoc Tukey's test found that samples T1 and T2; T1 and T3; T2 and T3 differed statistically significantly. The highest amount of protein within the fraction of  $\omega 5$  gliadins was obtained in T2 samples ( $X_{av}=2.17$ ), and the lowest in T3 samples ( $X_{av}=1.17$ ). Within the  $\omega 1,2$  gliadin fraction, the highest amount of protein was obtained in T1 samples ( $X_{av}=3.00$ ), and the lowest in T3 samples ( $X_{av}=1.83$ ). The highest amount of protein within the  $\alpha + \beta$  gliadin fraction was obtained in T1 samples ( $X_{av}=5.17$ ), and the lowest in T3 samples ( $X_{av}=3.83$ ). Within the  $\gamma$  gliadin fraction, the highest amount of protein was obtained in T1 samples ( $X_{av}=5.33$ ), and the lowest in T2 and T3 samples ( $X_{av}=2.50$ ). Table 2 shows the total amount of gliadin proteins (TAP) and the amount of protein within fractions ( $\omega 5$ ,  $\omega 1,2$ ,  $\alpha + \beta$  and  $\gamma$  gliadins) obtained on an HPLC apparatus, with absorbance measured at 280 nm.

The highest total amount of protein was obtained in T1 samples ( $X_{av}=15.17$ ), and the lowest in T3 samples ( $X_{av}=8.83$ ). One-factor analysis of the variance of different groups showed that there is a statistically significant difference,  $F(2.15)=43.04$ ,  $\text{Sig.}=0.000<0.05$ . The post-hoc Tukey test showed that samples T1 and T2; T1 and T3; T2 and T3 differed statistically significantly. Within the  $\omega 5$  gliadin fraction, the highest amount of protein was obtained in T1 samples ( $X_{av}=1.83$ ), and the lowest in T3 samples ( $X_{av}=1.50$ ). The highest amount of protein within the  $\omega 1,2$  gliadin fraction was obtained in T1 samples ( $X_{av}=3.00$ ), and the lowest in T3 sam-

ples ( $X_{av}=2.33$ ). Within the  $\alpha + \beta$  gliadin fraction, the highest amount of protein was obtained in T2 samples ( $X_{av}=5.50$ ), and the lowest in T3 samples ( $X_{av}=3.17$ ). Within the  $\gamma$  gliadin fraction the highest amount of protein was obtained in T1 samples ( $X_{av}=6.00$ ), and the lowest in T3 samples ( $X_{av}=2.17$ ). Table 3 shows the total amount of glutenin proteins (TAP), the amount of protein within fractions ( $\omega b$  gliadins, HMW and LMW glutenins) obtained from gluten-free flour samples and separated on an HPLC apparatus, with absorbance measured at 210 nm.

Based on the obtained results, the highest total amount of protein was obtained in T1 samples ( $X_{av}=13.67$ ), and the lowest in T3 samples ( $X_{av}=7.17$ ). One-factor analysis of the variance of different groups showed that there was a statistically significant difference,  $F(2.15)=78.56$ ,  $\text{Sig.}=0.000<0.05$ . The post-hoc Tukey test showed that samples T1 and T2; T1 and T3; T2 and T3 differed statistically significantly. Within the  $\omega b$  gliadin fraction, the highest amount of protein was obtained in T1 samples ( $X_{av}=4.50$ ), and the lowest in T3 samples ( $X_{av}=0.50$ ). The highest amount of protein within the HMW glutenin fraction was obtained in T1 samples ( $X_{av}=4.50$ ), and the lowest in T3 samples ( $X_{av}=2.00$ ). Within the LMW glutenin fraction, the highest amount of protein was obtained in T2 samples ( $X_{av}=5.00$ ), and the lowest in T1 and T3 samples ( $X_{av}=4.67$ ). Table 4 shows the total amount of glutenin proteins (TAP), the amount of protein within fractions

**Table 2.** TAP and amount of gliadin proteins by fractions ( $\omega 5$ ,  $\omega 1,2$ ,  $\alpha + \beta$  and  $\gamma$  gliadins) from gluten-free flour observed during RP-HPLC analysis; solvent: 70% (v/v) ethanol; absorbance measurement at 280 nm.

Treatments		N	Xav	SD	Std. error	Min	Max
Total number of proteins (TAP)	T1	6	15.17	0.98	0.40	14	17
	T2	6	13.00	1.41	0.58	11	15
	T3	6	8.83	1.17	0.48	8	11
$\omega 5$ gliadins	T1	6	1.83	0.41	0.17	1	2
	T2	6	1.67	0.52	0.21	1	2
	T3	6	1.50	0.55	0.22	1	2
$\omega 1,2$ gliadins	T1	6	3.00	0.63	0.26	2	4
	T2	6	2.67	0.82	0.33	2	4
	T3	6	2.33	0.52	0.21	2	3
$\alpha + \beta$ gliadins	T1	6	4.33	0.82	0.33	3	5
	T2	6	5.50	0.55	0.22	5	6
	T3	6	3.17	0.75	0.31	2	4
$\gamma$ gliadins	T1	6	6.00	1.26	0.52	5	8
	T2	6	3.17	0.98	0.40	2	4
	T3	6	2.17	0.41	0.17	2	3
ANOVA (TNP)		F(2.15)=43.04, Sig.=0.000, eta square=124.33/146.00=0.85					
ANOVA ( $\omega 5$ )		F(2.15)=0.68, Sig.=0.52>0.05					
ANOVA ( $\omega 1,2$ )		F(2.15)=1.50, Sig.=0.25>0.05					
ANOVA ( $\alpha + \beta$ )		F(2.15)=15.98, Sig.=0.000<0.05, eta square=16.33/24.00=0.68					
ANOVA ( $\gamma$ )		F(2.15)=26.04, Sig.=0.000<0.05, eta square=47.44/61.11=0.78					

T1 – CONTROL, T2 – extracts treated with plasma for 4 min and T3-extracts treated for 1 min after extraction.  
Xav – the average amount of isolated proteins, SD – standard deviation.

**Table 3.** TAP and amount of glutenin proteins by fractions ( $\omega b$  gliadins, HMW and LMW glutenins) from gluten-free flour observed during RP-HPLC analysis; solvent: 50% (v/v) 1-propanol to which Tris-HCl (0.05 mol/l, pH=7.5), urea (2 mol/l) and dithioerythritol (1%) were added; absorbance measurement at 210 nm.

Treatments		N	Xav	SD	Std. error	Min	Max
Total amount of proteins (TAP)	T1	6	13.67	0.82	0.33	13	15
	T2	6	10.00	0.89	0.36	9	11
	T3	6	7.17	0.98	0.40	6	9
$\omega b$ gliadins	T1	6	4.50	0.55	0.22	4	5
	T2	6	2.33	0.52	0.21	2	3
	T3	6	0.50	0.55	0.22	0	1
HMW glutenins	T1	6	4.50	0.55	0.22	4	5
	T2	6	2.67	0.82	0.33	2	4
	T3	6	2.00	0.00	0.00	2	2
LMW glutenins	T1	6	4.67	1.03	0.42	3	6
	T2	6	5.00	0.89	0.36	4	6
	T3	6	4.67	0.82	0.33	4	6
ANOVA (TNP)		F(2.15)=78.56, Sig.=0.000, eta square=127.44/139.61=0.91					
ANOVA ( $\omega b$ )		F(2.15)=83.27, Sig.=0.000, eta square=48.11/52.44=0.92					
ANOVA (HMW)		F(2.15)=31.21, Sig.=0.000, eta square=20.11/24.94=0.81					
ANOVA (LMW)		F(2.15)=0.26, Sig.=0.77>0.05					

T1 – CONTROL, T2 – extracts treated with plasma for 4 min and T3 – extracts treated for 1 min after extraction.  
Xav – the average amount of isolated proteins, SD – standard deviation.

( $\omega b$  gliadins, HMW and LMW glutenins) obtained from gluten-free flour samples and separated on an HPLC apparatus, with absorbance measured at 280 nm.

Based on the obtained results, the highest total amount of protein was obtained in T1 samples (Xav=13.33), and the lowest in T3 samples (Xav=7.00). One-factor analysis of variance of different groups showed that there is a statistically significant difference,

F(2.15)=74.45, Sig.=0.000. The post-hoc Tukey test showed that samples T1 and T2; T1 and T3; and T2 and T3 differed statistically significantly. The highest amount of protein within the fraction of  $\omega b$  gliadins was obtained in T1 samples (Xav=4.17), and the lowest in T3 samples (Xav=1.17). Within the HMW glutenin fraction, the highest amount of protein was obtained in T1 samples (Xav=3.83), and the lowest in T3 samples (Xav=1.50).

**Table 4.** TAP and amount of glutenin proteins by fractions ( $\omega$ b gliadins, HMW and LMW glutenins) from gluten-free flour observed during RP-HPLC analysis; solvent: 50% (v/v) 1-propanol to which Tris-HCl (0.05 mol/l, pH=7.5), urea (2 mol/l) and dithioerythritol (1%) were added; absorbance measurement at 280 nm.

Treatments		N	Xav	SD	Std. error	Min	Max
Total amount of proteins (TAP)	T1	6	13.33	0.52	0.21	13	14
	T2	6	9.83	1.17	0.48	8	11
	T3	6	7.00	0.89	0.36	6	8
$\omega$ b gliadins	T1	6	4.17	0.41	0.17	4	5
	T2	6	2.33	0.52	0.21	2	3
	T3	6	1.17	0.41	0.17	1	2
HMW glutenins	T1	6	3.83	0.98	0.40	3	5
	T2	6	3.00	0.63	0.26	2	4
	T3	6	1.50	0.55	0.22	1	2
LMW glutenins	T1	6	5.33	0.82	0.33	4	6
	T2	6	4.50	0.55	0.22	4	5
	T3	6	4.33	0.52	0.21	4	5
ANOVA (TNP)		F(2,15)=74.45, Sig.=0.000, eta square=120.78/132.94=0.91					
ANOVA ( $\omega$ b)		F(2,15)=68.61, Sig.=0.000, eta square=27.44/30.44=0.90					
ANOVA (HMW)		F(2,15)=15.10, Sig.=0.000, eta square=16.78/25.11=0.67					
ANOVA (LMW)		F(2,15)=4.19, Sig.=0.04<0.05, eta square=3.44/9.61=0.36					

T1 – CONTROL, T2 – extracts treated with plasma for 4 min and T3 – extracts treated for 1 min after extraction.  
Xav – the average amount of isolated proteins, SD – standard deviation.

The highest amount of protein within the LMW glutenin fraction was obtained in T1 samples (Xav=5.33), and the lowest in T3 samples (Xav=4.33). Table 5 shows the total relative concentration (TRC), the relative concentration of protein within fractions  $\omega$ 5,  $\omega$ 1.2,  $\alpha$ + $\beta$  and  $\gamma$  gliadin) obtained from gluten-free flour samples and separated on an HPLC apparatus, with absorbance measured at 210 nm.

Based on the obtained results, the highest relative concentration within the  $\omega$ 5 gliadin fraction was obtained in T2 samples (RC=9.98%), and the lowest in T1 samples (RC=4.67%). The highest relative concentration within the  $\omega$ 1.2 gliadin fraction was obtained in T1 samples (RC=7.34%), and the lowest in T3 samples (RC=4.43%). Within the  $\alpha$ + $\beta$  gliadin fraction, the highest relative concentration was obtained in T1 samples (RC=40.58%) and the lowest in T3 samples (RC=23.63%). The highest relative concentration within the  $\gamma$  gliadin fraction was obtained in T3 samples (RC=60.23%), and the lowest in T2 samples (RC=47.24%). Table 6 shows the total relative concentration (TRC), the relative concentration of protein within fractions ( $\omega$ 5,  $\omega$ 1.2,  $\alpha$ + $\beta$  and  $\gamma$  gliadin) obtained from gluten-free flour samples and separated on an HPLC apparatus, english with absorbance measured at 280 nm.

The highest relative concentration within the  $\omega$ 5 gliadin fraction was obtained in T2 samples (RC=17.06%), and the lowest in T3 samples (RC=4.39%). Within the  $\omega$ 1.2 gliadin fraction, the highest relative concentration was obtained in T1 samples (RC=4.59%) and the lowest in T3 samples (RC=2.23%). The highest relative concentration within the  $\alpha$ + $\beta$  gliadin fraction was obtained in T1 samples (RC=28.61),

and the lowest in T2 sample (RC=6.42%). Within the  $\gamma$  gliadin fraction, the highest relative concentration was obtained in T3 samples (RC=82.70%), and the lowest in T1 samples (RC=59.44%). Table 7 shows the total relative concentration (TRC), the relative concentration of protein within fractions ( $\omega$ b gliadins, HMW and LMW glutenins) obtained from gluten-free flour samples and separated on an HPLC apparatus, with absorbance measured at 210 nm.

The highest relative concentration within the  $\omega$ b gliadin fraction was obtained in T3 samples (RC=2.60%), and the lowest in T2 samples (RC=1.29%). Within the HMW glutenin fraction, the highest relative concentration was obtained in T3 samples (RC=16.63%), and the lowest in T1 samples (RC=3.04%), and within the LMW glutenin fraction, the highest relative concentration was obtained in T1 samples (RC=94.60%), and the lowest in T3 samples (RC=80.77%). Table 8 shows the total relative concentration (TRC), the relative concentration of protein within fractions ( $\omega$ b gliadins, HMW and LMW glutenins) obtained from gluten-free flour samples and separated on an HPLC apparatus, with absorbance measured at 280 nm.

Based on the obtained results, the highest relative concentration within the  $\omega$ b gliadin fraction was obtained in T2 samples (RC=8.51%), and the lowest in T3 samples (RC=1.54%). Within the HMW glutenin fraction, the highest relative concentration was obtained in T3 samples (RC=16.24%) and the lowest in T1 samples (RC=6.17%), while within the LMW glutenin fraction, the highest relative concentration was obtained in T1 samples (RC=89.16%), and the lowest in T2 samples

**Table 5.** TRC and relative concentration of gliadin by fractions ( $\omega 5$ ,  $\omega 1.2$ ,  $\alpha + \beta$  and  $\gamma$  gliadin) observed during RP-HPLC analysis of gluten-free flour; solvent: 70% (v/v) ethanol; absorbance measurement at 210 nm.

Treatments		N	RC (%)	SD	Std. error	Min	Max
Total relative concentration (TRC)	T1	6	100	0.00	0.00	100	100
	T2	6	100	0.00	0.00	100	100
	T3	6	100	0.00	0.00	100	100
$\omega 5$ gliadins	T1	6	4.67	0.67	0.27	3.81	5.38
	T2	6	9.98	1.06	0.43	8.14	11.34
	T3	6	9.61	0.68	0.28	8.48	10.29
$\omega 1.2$ gliadins	T1	6	7.34	0.74	0.30	6.43	8.35
	T2	6	6.60	0.88	0.36	5.89	8.16
	T3	6	4.43	0.92	0.38	5.12	7.75
$\alpha + \beta$ gliadins	T1	6	40.58	1.57	0.64	37.53	41.66
	T2	6	36.17	2.24	0.92	33.84	39.28
	T3	6	23.63	1.87	0.76	21.11	25.82
$\gamma$ gliadins	T1	6	47.40	1.31	0.54	45.89	49.20
	T2	6	47.24	3.01	1.23	42.26	50.14
	T3	6	60.23	2.26	0.92	56.14	62.68
ANOVA ( $\omega 5$ )		F(2,15)=78.11, Sig.=0.000, eta square=105.62/115.76=0.91					
ANOVA ( $\omega 1.2$ )		F(2,15)=1.92, Sig.=0.18>0.05					
ANOVA ( $\alpha + \beta$ )		F(2,15)=126.81, Sig.=0.000, eta square=928.49/983.40=0.94					
ANOVA ( $\gamma$ )		F(2,15)=63.81, Sig.=0.000, eta square=676.08/755.54=0.89					

T1 textendash CONTROL, T2 textendash extracts treated with plasma for 4 min and T3 textendash extracts treated for 1 min after extraction, RC – relative concentration, SD – standard deviation.

**Table 6.** TRC and relative concentration of gliadin by fractions observed during RP-HPLC analysis of gluten-free flour; solvent: 70% (v/v) ethanol; absorbance measurement at 280 nm.

Treatments		N	RC (%)	SD	Std. Error	Min	Max
Total relative concentration (TRC)	T1	6	100	0.00	0.00	100	100
	T2	6	100	0.00	0.00	100	100
	T3	6	100	0.00	0.00	100	100
$\omega 5$ gliadins	T1	6	7.36	0.78	0.32	6.27	8.23
	T2	6	17.06	0.49	0.20	16.42	17.70
	T3	6	4.39	0.67	0.27	3.67	5.49
$\omega 1.2$ gliadins	T1	6	4.59	0.72	0.29	3.96	5.92
	T2	6	3.74	0.30	0.12	3.32	4.18
	T3	6	2.23	0.35	0.14	1.92	2.84
$\alpha + \beta$ gliadins	T1	6	28.61	0.87	0.36	27.44	29.87
	T2	6	6.42	1.06	0.43	5.33	7.76
	T3	6	10.68	1.79	0.73	9.11	13.52
$\gamma$ gliadins	T1	6	59.44	1.32	0.54	57.09	60.48
	T2	6	72.79	1.16	0.48	70.76	74.06
	T3	6	82.70	1.99	0.81	79.48	84.73
ANOVA ( $\omega 5$ )		F(2,15)=606.23, Sig.=0.000, eta square=526.64/533.16=0.99					
ANOVA ( $\omega 1.2$ )		F(2,15)=35.02, Sig.=0.000, eta square=17.08/20.73=0.82					
ANOVA ( $\alpha + \beta$ )		F(2,15)=489.21, Sig.=0.000, eta square=1664.50/1690.01=0.69					
ANOVA ( $\gamma$ )		F(2,15)=347.22, Sig.=0.000, eta square=1634.85/1670.16=0.98					

T1 – CONTROL, T2 – extracts treated with plasma for 4 min and T3 – extracts treated for 1 min after extraction, RC – relative concentration, SD – standard deviation.

(RC=75.44%). In his research, [Nooji \(2011\)](#) came to the conclusion that the allergenicity of wheat decreased by 37% after treatment with DBD plasma for 5 minutes. [Hajnal et al. \(2019\)](#) treated wheat flour with cold atmospheric plasma and monitored the *Alternaria* toxin content. After the treatment, the *Alternaria* toxin content was reduced. [Upadhyay, Thirumdas, Deshmukh, Annapure, and Misra \(2019\)](#) investigated the influence of low-

pressure cold plasma on the modification of the properties of chia flour. The obtained results showed a significant change in the color of the flour, with an increase in lightness. [Sun et al. \(2020\)](#) determined the structural properties and immunoreactivity of celiac-toxic peptides after treatment with cold jet atmospheric plasma (CJAP). The mentioned properties and immunoreactivity were determined by the enzyme-immunochemical method (ELISA).

**Table 7.** TRC and relative concentration of glutenins by fractions ( $\omega$ b gliadins, HMW and LMW glutenins) observed during RP-HPLC analysis of gluten-free flour; solvent: 50% (v/v) 1-propanol to which Tris-HCl (0.05 mol/l, pH=7.5), urea (2 mol/l) and dithioerythritol (1%) were added; absorbance measurement at 210 nm.

Treatments		N	RC (%)	SD	Std. Error	Min	Max
Total relative concentration (TRC)	T1	6	100	0.00	0.00	100	100
	T2	6	100	0.00	0.00	100	100
	T3	6	100	0.00	0.00	100	100
$\omega$ b gliadins	T1	6	2.36	0.30	0.12	1.91	2.76
	T2	6	1.29	0.22	0.09	1.01	1.66
	T3	6	2.60	0.26	0.11	2.28	2.97
HMW glutenins	T1	6	3.04	0.38	0.16	2.49	3.50
	T2	6	10.05	0.68	0.28	8.80	10.63
	T3	6	16.63	0.98	0.40	15.28	18.16
LMW glutenins	T1	6	94.60	0.50	0.20	93.93	95.28
	T2	6	88.66	0.87	0.36	87.71	90.19
	T3	6	80.77	0.85	0.35	79.56	81.75
ANOVA ( $\omega$ b)		F(2.15)=42.59, Sig.=0.000, eta square=5.86/6.89=0.85					
ANOVA (HMW)		F(2.15)=526.73, Sig.=0.000, eta square=553.98/561.87=0.98					
ANOVA (LMW)		F(2.15)=498.05, Sig.=0.000, eta square=577.60/586.29=0.98					

T1 – CONTROL, T2 – extracts treated with plasma for 4 min and T3 – extracts treated for 1 min after extraction, RC– relative concentration, SD – standard deviation.

**Table 8.** TRC and relative concentration of glutenins by fractions ( $\omega$ b gliadins, HMW and LMW glutenins) observed during RP-HPLC analysis of gluten-free flour; solvent: 50% (v/v) 1-propanol to which Tris-HCl (0.05 mol/l, pH=7.5), urea (2 mol/l) and dithioerythritol (1%) were added; absorbance measurement at 280 nm.

Treatments		N	RC (%)	SD	Std. error	Min	Max
Total relative concentration (TRC)	T1	6	100	0.00	0.00	100	100
	T2	6	100	0.00	0.00	100	100
	T3	6	100	0.00	0.00	100	100
$\omega$ b gliadins	T1	6	4.67	0.72	0.29	3.71	5.70
	T2	6	8.51	0.35	0.14	8.07	8.96
	T3	6	1.54	0.12	0.05	1.32	1.67
HMW glutenins	T1	6	6.17	0.93	0.38	4.91	7.59
	T2	6	16.05	1.02	0.42	14.48	17.21
	T3	6	16.24	1.47	0.60	14.59	18.12
LMW glutenins	T1	6	89.16	1.33	0.54	86.71	90.29
	T2	6	75.44	1.24	0.51	73.83	77.36
	T3	6	82.22	1.56	0.64	80.21	84.09
ANOVA ( $\omega$ b)		F(2.15)=337.22, Sig.=0.000, eta square=146.59/149.58=0.98					
ANOVA (HMW)		F(2.15)=146.74, Sig.=0.000, eta square=397.98/418.32=0.95					
ANOVA (LMW)		F(2.15)=146.81, Sig.=0.000, eta square=564.74/593.59=0.95					

T1 – CONTROL, T2 – extracts treated with plasma for 4 min and T3 – extracts treated for 1 min after extraction, RC – relative concentration, SD – standard deviation.

Based on the obtained results, gliadin concentration decreased after the treatment, and a significant decrease (51.95%) was observed for 60 minutes. A decrease in gliadin concentration led to a decrease in immunoreactivity. In the available literature, the effect of cold atmospheric plasma on gluten proteins extracted from gluten-free flours has not been investigated. However, when the results obtained in this paper are compared with the results of Nooji (2011) and Sun et al. (2020) who investigated the effect of cold atmospheric plasma on gluten proteins from wheat flour, it can be seen that they are in agreement. In this paper, it was shown that cold atmospheric plasma leads to a decrease in the total amount of

proteins after treatment of samples when compared with control samples. Plasma treatment leads to the separation of large polymers into the monomers from which they are composed.

#### 4. CONCLUSION

After treatment of gluten proteins obtained from gluten-free flour samples with cold atmospheric plasma (solid samples for 4 min and extracts for 1 min) and then separation by RP-HPLC chromatography, the following conclusions were reached. Plasma treatment leads to a reduction in the total amount of proteins compared to un-

treated samples. A higher reduction in the total amount of proteins was obtained when proteins were treated as extracts compared to solid samples.

## REFERENCES

- Balakireva, A., & Zamyatnin, A. (2016). Properties of gluten intolerance: Gluten structure, evolution, pathogenicity and detoxification capabilities. *Nutrients*, 8(10), 644. <https://doi.org/10.3390/nu8100644>
- Caio, G., Volta, U., Sapone, A., Leffler, D. A., Giorgio, R. D., Catassi, C., & Fasano, A. (2019). Celiac disease: a comprehensive current review. *BMC Medicine*, 17(1). <https://doi.org/10.1186/s12916-019-1380-z>
- Camirero, A., & Verdu, E. F. (2019). Celiac disease: should we care about microbes? *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 317(2), G161–G170. <https://doi.org/10.1152/ajpgi.00099.2019>
- Cianferoni, A. (2016). Wheat allergy: diagnosis and management. *Journal of Asthma and Allergy*, 13. <https://doi.org/10.2147/jaa.s81550>
- Codex Alimentarius Commission and others. (2008). Codex standard for foods for special dietary use for persons intolerant to gluten. [http://www.codexalimentarius.net/download/standards/291/cxs\\_118e.pdf](http://www.codexalimentarius.net/download/standards/291/cxs_118e.pdf)
- Elli, L., Branchi, F., Tomba, C., Villalta, D., Norsa, L., Ferretti, F., ... Bardella, M. T. (2015). Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity. *World Journal of Gastroenterology*, 21(23), 7110–7119. <https://doi.org/10.3748/wjg.v21.i23.7110>
- El-Sayed, Z., & Shousha, G. (2020). Wheat allergy. *The Egyptian Journal of Pediatric Allergy and Immunology*, 18(2), 55–60.
- Gojković-Cvjetković, V., Grujić, R., Marjanović-Balaban, Ž., Stanojević, L., Stanojević, J., & Cakić, M. (2019). Gliadin analysis by reversed-phase high performance liquid chromatography. *Advanced Technologies*, 8(2), 30–36. <https://doi.org/10.5937/savteh1902030g>
- Gujral, N. (2012). Celiac disease: Prevalence, diagnosis, pathogenesis and treatment. *World Journal of Gastroenterology*, 18(42), 6036. <https://doi.org/10.3748/wjg.v18.i42.6036>
- Gumienna, M., & Górna, B. (2020). Gluten hypersensitivities and their impact on the production of gluten-free beer. *European Food Research and Technology*, 246(11), 2147–2160. <https://doi.org/10.1007/s00217-020-03579-9>
- Hajnal, E. J., Vukić, M., Pezo, L., Orčić, D., Puač, N., Škoro, N., ... Simović, D. Š. (2019). Effect of atmospheric cold plasma treatments on reduction of alternaria toxins content in wheat flour. *Toxins*, 11(12), 704. <https://doi.org/10.3390/toxins11120704>
- Holmes, G. (2013). Non coeliac gluten sensitivity. *Gastroenterology and Hepatology from Bed to Bench*, 6(3), 115.
- Itzlinger, A., Branchi, F., Elli, L., & Schumann, M. (2018). Gluten-free diet in celiac disease—forever and for all? *Nutrients*, 10(11), 1796. <https://doi.org/10.3390/nu10111796>
- Khairuddin, M. A. N., & Lasekan, O. (2021). Gluten-free cereal products and beverages: A review of their health benefits in the last five years. *Foods*, 10(11), 2523. <https://doi.org/10.3390/foods10112523>
- Kumar, P. (2014). Role of gluten protein in the food products of living beings and its effect on their body both physicochemical and metabolically reactions. *International Research Journal of Commerce Arts and Science*, 5(3), 65–83.
- Lionetti, E., & Catassi, C. (2015). The role of environmental factors in the development of celiac disease: What is new? *Diseases*, 3(4), 282–293. <https://doi.org/10.3390/diseases3040282>
- Nooji, J. K. (2011). *Reduction of wheat allergen potency by pulsed ultraviolet light, high hydrostatic pressure, and non-thermal plasma* (Unpublished doctoral dissertation). University of Florida.
- Pilolli, R., Gadaleta, A., Stasio, L. D., Lamonaca, A., Angelis, E. D., Nigro, D., ... Monaci, L. (2019). A comprehensive peptidomic approach to characterize the protein profile of selected durum wheat genotypes: Implication for coeliac disease and wheat allergy. *Nutrients*, 11(10), 2321. <https://doi.org/10.3390/nu11102321>
- Rai, S., Kaur, A., & Chopra, C. S. (2018). Gluten-free products for celiac susceptible people. *Frontiers in Nutrition*, 5. <https://doi.org/10.3389/fnut.2018.00116>
- Saturni, L., Ferretti, G., & Bacchetti, T. (2010). The gluten-free diet: Safety and nutritional quality. *Nutrients*, 2(1), 16–34. <https://doi.org/10.3390/nu2010016>
- Schalk, K., Lexhaller, B., Koehler, P., & Scherf, K. A. (2017). Isolation and characterization of gluten protein types from wheat, rye, barley and oats for use as reference materials. *PLOS ONE*, 12(2), e0172819. <https://doi.org/10.1371/journal.pone.0172819>
- Serena, G., D'Avino, P., & Fasano, A. (2020). Celiac disease and non-celiac wheat sensitivity: State of art of non-dietary therapies. *Frontiers in Nutrition*, 7. <https://doi.org/10.3389/fnut.2020.00152>
- Sergi, C., Villanacci, V., & Carroccio, A. (2021). Non-celiac wheat sensitivity: rationality and irrationality of a gluten-free diet in individuals affected with non-celiac disease: a review. *BMC Gastroenterology*, 21(1). <https://doi.org/10.1186/s12876-020-01568-6>
- Shewry, P. (2019). What is gluten—why is it special? *Frontiers in Nutrition*, 6. <https://doi.org/10.3389/fnut.2019.00101>
- Silano, M. (2010). Effect of the timing of gluten introduction on the development of celiac disease. *World Journal of Gastroenterology*, 16(16), 1939. <https://doi.org/10.3748/wjg.v16.i16.1939>
- Sun, F., Xie, X., Zhang, Y., Duan, J., Ma, M., Wang, Y., ... He, G. (2020). Effects of cold jet atmospheric pressure plasma on the structural characteristics and immunoreactivity of celiac-toxic peptides and wheat storage proteins. *International Journal of Molecular Sciences*, 21(3), 1012. <https://doi.org/10.3390/ijms21031012>
- Taraghikhah, N., Ashtari, S., Asri, N., Shahbazkhani, B., Al-Dulaimi, D., Rostami-Nejad, M., ... Zali, M. R. (2020). An updated overview of spectrum of gluten-related disorders: clinical and diagnostic aspects. *BMC Gastroenterology*, 20(1). <https://doi.org/10.1186/s12876-020-01390-0>



- Upadhyay, R., Thirumdas, R., Deshmukh, R. R., Annapure, U., & Misra, N. N. (2019). An exploration of the effects of low-pressure plasma discharge on the physicochemical properties of chia (*salvia hispanica* l.) flour. *JOURNAL OF ENGINEERING & PROCESSING MANAGEMENT*, 11(2). <https://doi.org/10.7251/jepm1902073u>
- Vensel, W. H., Tanaka, C. K., & Altenbach, S. B. (2014). Protein composition of wheat gluten polymer fractions determined by quantitative two-dimensional gel electrophoresis and tandem mass spectrometry. *Proteome Science*, 12(1), 8. <https://doi.org/10.1186/1477-5956-12-8>
- Walter, T. (2014). Degradation of gluten in wheat bran and bread drink by means of a proline-specific peptidase. *Journal of Nutrition & Food Sciences*, 04(05). <https://doi.org/10.4172/2155-9600.1000293>
- Wieser, H. (2007). Chemistry of gluten proteins. *Food Microbiology*, 24(2), 115–119. <https://doi.org/10.1016/j.fm.2006.07.004>
- Wieser, H., Antes, S., & Seilmeier, W. (1998). Quantitative determination of gluten protein types in wheat flour by reversed-phase high-performance liquid chromatography. *Cereal Chemistry Journal*, 75(5), 644–650. <https://doi.org/10.1094/cchem.1998.75.5.644>
- Wieser, H., Ruiz-Carnicer, Á., Segura, V., Comino, I., & Sousa, C. (2021). Challenges of monitoring the gluten-free diet adherence in the management and follow-up of patients with celiac disease. *Nutrients*, 13(7), 2274. <https://doi.org/10.3390/nu13072274>
- Wieser, H., Segura, V., Ruiz-Carnicer, Á., Sousa, C., & Comino, I. (2021). Food safety and cross-contamination of gluten-free products: A narrative review. *Nutrients*, 13(7), 2244. <https://doi.org/10.3390/nu13072244>